Does the media refer more to PROK or HURA?

In the previous week, TuHURA Biosciences had 8 more articles in the media than ProKidney. MarketBeat recorded 12 mentions for TuHURA Biosciences and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.37 beat TuHURA Biosciences' score of -0.05 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HURA or PRTA?

In the previous week, TuHURA Biosciences had 10 more articles in the media than Prothena. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Prothena. Prothena's average media sentiment score of 1.92 beat TuHURA Biosciences' score of -0.05 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, KYTX or HURA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is KYTX or HURA more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% TuHURA Biosciences N/A -156.12% -105.38%

Does the media prefer KYTX or HURA?

In the previous week, TuHURA Biosciences had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 7 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.33 beat TuHURA Biosciences' score of -0.05 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HURA or OVID?

In the previous week, TuHURA Biosciences had 9 more articles in the media than Ovid Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 3 mentions for Ovid Therapeutics. TuHURA Biosciences' average media sentiment score of -0.05 beat Ovid Therapeutics' score of -0.19 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TuHURA Biosciences (HURA) Competitors

$2.19 +0.07 (+3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$2.17 -0.02 (-0.82%)

As of 07:57 PM Eastern

Compare

HURA vs. GYRE, PROK, PRTA, KYTX, and OVID

Should you buy TuHURA Biosciences stock or one of its competitors? MarketBeat compares TuHURA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TuHURA Biosciences include Gyre Therapeutics (GYRE), ProKidney (PROK), Prothena (PRTA), Kyverna Therapeutics (KYTX), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry.

How does TuHURA Biosciences compare to Gyre Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TuHURA Biosciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, TuHURA Biosciences had 12 more articles in the media than Gyre Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat TuHURA Biosciences' score of -0.05 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Gyre Therapeutics	Very Positive

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 310.96%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 174.64%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe TuHURA Biosciences is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Gyre Therapeutics has higher revenue and earnings than TuHURA Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Gyre Therapeutics	$117.05M	5.13	$5.03M	-$0.09	N/A

Summary

Gyre Therapeutics beats TuHURA Biosciences on 9 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to ProKidney?

ProKidney (NASDAQ:PROK) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

ProKidney currently has a consensus price target of $7.40, suggesting a potential upside of 300.00%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 310.96%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ProKidney has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TuHURA Biosciences has lower revenue, but higher earnings than ProKidney. TuHURA Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	627.88	-$68.99M	-$0.53	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

TuHURA Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
TuHURA Biosciences	N/A	-156.12%	-105.38%

In the previous week, TuHURA Biosciences had 8 more articles in the media than ProKidney. MarketBeat recorded 12 mentions for TuHURA Biosciences and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.37 beat TuHURA Biosciences' score of -0.05 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats TuHURA Biosciences on 10 of the 16 factors compared between the two stocks.

How does TuHURA Biosciences compare to Prothena?

TuHURA Biosciences (NASDAQ:HURA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

TuHURA Biosciences has higher earnings, but lower revenue than Prothena. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Prothena	$9.68M	50.02	-$244.09M	-$2.82	N/A

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 310.96%. Prothena has a consensus target price of $23.75, indicating a potential upside of 156.76%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

TuHURA Biosciences has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Prothena	-260.92%	-43.44%	-36.87%

In the previous week, TuHURA Biosciences had 10 more articles in the media than Prothena. MarketBeat recorded 12 mentions for TuHURA Biosciences and 2 mentions for Prothena. Prothena's average media sentiment score of 1.92 beat TuHURA Biosciences' score of -0.05 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

TuHURA Biosciences and Prothena tied by winning 8 of the 16 factors compared between the two stocks.

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Kyverna Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 277.36%. TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 310.96%. Given TuHURA Biosciences' higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, TuHURA Biosciences had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 7 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.33 beat TuHURA Biosciences' score of -0.05 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyverna Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Kyverna Therapeutics' return on equity of -81.88% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
TuHURA Biosciences	N/A	-156.12%	-105.38%

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kyverna Therapeutics beats TuHURA Biosciences on 7 of the 11 factors compared between the two stocks.

How does TuHURA Biosciences compare to Ovid Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

TuHURA Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 310.96%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 106.65%. Given TuHURA Biosciences' higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

TuHURA Biosciences has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Ovid Therapeutics has higher revenue and earnings than TuHURA Biosciences. Ovid Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Ovid Therapeutics	$7.25M	63.84	-$17.41M	-$0.29	N/A

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, TuHURA Biosciences had 9 more articles in the media than Ovid Therapeutics. MarketBeat recorded 12 mentions for TuHURA Biosciences and 3 mentions for Ovid Therapeutics. TuHURA Biosciences' average media sentiment score of -0.05 beat Ovid Therapeutics' score of -0.19 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TuHURA Biosciences has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Summary

Ovid Therapeutics beats TuHURA Biosciences on 11 of the 16 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$135.01M	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	-3.59	18.46	24.03	24.35
Price / Sales	N/A	317.64	518.85	115.59
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	6.44	6.77	9.98	6.72
Net Income	-$30.05M	$24.09M	$3.56B	$337.03M
7 Day Performance	-6.81%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-22.34%	48.90%	28.76%	33.98%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	1.8863 of 5 stars	$2.19 +3.3%	$9.00 +311.0%	-27.6%	$135.01M	N/A	N/A	N/A	Analyst Revision
GYRE Gyre Therapeutics	2.4316 of 5 stars	$5.86 -0.9%	$17.00 +190.4%	-30.8%	$573.44M	$117.05M	N/A	40
PROK ProKidney	1.9669 of 5 stars	$1.79 -2.3%	$7.40 +314.1%	+122.0%	$552.77M	$890K	N/A	3
PRTA Prothena	3.0446 of 5 stars	$9.34 -8.3%	$23.75 +154.4%	+84.7%	$532.96M	$9.68M	N/A	130	Positive News Analyst Downgrade Insider Trade
KYTX Kyverna Therapeutics	2.3157 of 5 stars	$7.91 -7.1%	$30.00 +279.1%	+180.3%	$517.97M	N/A	N/A	96	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. GYRE, PROK, PRTA, KYTX, and OVID

How does TuHURA Biosciences compare to Gyre Therapeutics?

Summary

How does TuHURA Biosciences compare to ProKidney?

Summary

How does TuHURA Biosciences compare to Prothena?

Summary

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Summary

How does TuHURA Biosciences compare to Ovid Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. GYRE, PROK, PRTA, KYTX, and OVID

How does TuHURA Biosciences compare to Gyre Therapeutics?

Do insiders & institutionals believe in HURA or GYRE?

Which has more volatility and risk, HURA or GYRE?

Is HURA or GYRE more profitable?

Does the media refer more to HURA or GYRE?

Do analysts rate HURA or GYRE?

Which has stronger earnings & valuation, HURA or GYRE?

Summary

How does TuHURA Biosciences compare to ProKidney?

Do analysts prefer PROK or HURA?

Which has more risk & volatility, PROK or HURA?

Do insiders & institutionals hold more shares of PROK or HURA?

Which has higher earnings and valuation, PROK or HURA?

Is PROK or HURA more profitable?

Does the media refer more to PROK or HURA?

Summary

How does TuHURA Biosciences compare to Prothena?

Which has more volatility and risk, HURA or PRTA?

Which has better earnings and valuation, HURA or PRTA?

Do insiders and institutionals believe in HURA or PRTA?

Do analysts recommend HURA or PRTA?

Is HURA or PRTA more profitable?

Does the media refer more to HURA or PRTA?

Summary

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Which has better earnings & valuation, KYTX or HURA?

Do analysts rate KYTX or HURA?

Does the media prefer KYTX or HURA?

Which has more volatility & risk, KYTX or HURA?

Is KYTX or HURA more profitable?

Do insiders and institutionals believe in KYTX or HURA?

Summary

How does TuHURA Biosciences compare to Ovid Therapeutics?

Do analysts recommend HURA or OVID?

Which has more risk and volatility, HURA or OVID?

Which has preferable valuation & earnings, HURA or OVID?

Do insiders & institutionals have more ownership in HURA or OVID?

Does the media refer more to HURA or OVID?

Is HURA or OVID more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools